Expand RARE Menu
RARE MENU

RARE Stock Posts


Unusual Option Volume

RARE Ultragenyx Pharmaceutical14.81-0.49 (-3.2%)

Ultragenyx Pharmaceutical trades 1,694 contracts. The company has the following event: on Sep 19, 2026.
View Details...
Unusual Option Volume

RARE Ultragenyx Pharmaceutical15.73+0.88 (+5.9%)

Ultragenyx Pharmaceutical trades 6,983 contracts. The company has the following event: on Sep 19, 2026.
View Details...
Unusual Option Volume

RARE Ultragenyx Pharmaceutical14.85-11.68 (-44.0%)

Ultragenyx Pharmaceutical trades 8,458 contracts. The company has the following event: on Sep 19, 2026. News: Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome
View Details...
RARE #UltragenyxPharmaceutical stock declines -43.3% in after hours trading. See the latest news.

After Hours Decliner

RARE Ultragenyx Pharmaceutical26.53+0.72+2.8%

After Hours:15.05-11.48 (-43.3%)

Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome

Globe NewswireWed, 2-Sep 4:01 PM
Unusual Option Volume

RARE Ultragenyx Pharmaceutical25.82-0.01 (0.0%)

Ultragenyx Pharmaceutical trades 1,712 contracts. The highest volume is in the 18-Dec-26 20 calls.
View Details...
RARE #UltragenyxPharmaceutical stock increases 6.9% after hours.

After Hours Gainer

RARE Ultragenyx Pharmaceutical26.24+0.75+2.9%

After Hours:28.04+1.80 (+6.9%)

Ultragenyx Announces U.S. FDA Approval of GENGLYCOS Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)

Globe NewswireWed, 19-Aug 5:21 PM
Load Earlier Posts
Market Data Delayed 15 Minutes